Drugs / QIV Control
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT06622590 Comparator | Oct 2024 → Jan 2025 overdue | influenza | Institute of Medical Biology, Chinese Academy of Medical Sciences | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06800950 Comparator | Feb → Jul 2025 overdue | influenza | Institute of Medical Biology, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QIV control | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06622590 ↗ |
| Modality | Vaccine | “Quadrivalent Influenza Virus Split Vaccine” NCT06622590 ↗ |